Oct 14, 2023
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
Read more
Oct 09, 2023
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
Read more
Oct 05, 2023
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
Read more
Aug 03, 2023
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
Read more
Jul 31, 2023
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Read more
Jul 27, 2023
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
Read more
Displaying 11 - 20 of 44